Anti-NOR90 antibodies and their clinical significance: a multicenter experience in southern Spain.

J Martínez de Victoria Carazo, D Fernández Reyes, F J de la Hera Fernández, T González Cejudo, N Navarrete Navarrete, J L Callejas Rubio
{"title":"Anti-NOR90 antibodies and their clinical significance: a multicenter experience in southern Spain.","authors":"J Martínez de Victoria Carazo, D Fernández Reyes, F J de la Hera Fernández, T González Cejudo, N Navarrete Navarrete, J L Callejas Rubio","doi":"10.1016/j.rceng.2024.10.008","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Anti-NOR90 antibodies were initially described in patients with autoimmune diseases based on staining of a nucleolar region known as the nucleolar organizer region (NOR). This study aims to explore the clinical aspects of anti-NOR90 antibodies in patients with systemic autoimmune diseases.</p><p><strong>Methods: </strong>Observational study of patients with positive anti-NOR90 antibodies using the EUROLINE Systemic Sclerosis profile (IgG) kit (Euroimmun, Germany). Data on demographics, comorbidities, autoimmune diseases, treatment, and clinical manifestations were collected.</p><p><strong>Results: </strong>Fifteen Patients with positive anti-NOR90 antibodies were included. Majority were female (86.7%), with median age of 54 years. Most common clinical manifestations were Raynaud's phenomenon, dryness, and interstitial lung disease (ILD). Some patients had hematological or solid organ neoplasms. EPID was prevalent, with one case showing rapid progression requiring aggressive treatment.</p><p><strong>Discussion and conclusion: </strong>This study highlights the association between anti-NOR90 antibodies and systemic autoimmune diseases, particularly SS and ES. EPID was a notable feature, suggesting its consideration in IPAF diagnosis for anti-NOR90 positive patients. Further multicenter studies are needed for better understanding and detection methods optimization.</p>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista clinica espanola","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.rceng.2024.10.008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Anti-NOR90 antibodies were initially described in patients with autoimmune diseases based on staining of a nucleolar region known as the nucleolar organizer region (NOR). This study aims to explore the clinical aspects of anti-NOR90 antibodies in patients with systemic autoimmune diseases.

Methods: Observational study of patients with positive anti-NOR90 antibodies using the EUROLINE Systemic Sclerosis profile (IgG) kit (Euroimmun, Germany). Data on demographics, comorbidities, autoimmune diseases, treatment, and clinical manifestations were collected.

Results: Fifteen Patients with positive anti-NOR90 antibodies were included. Majority were female (86.7%), with median age of 54 years. Most common clinical manifestations were Raynaud's phenomenon, dryness, and interstitial lung disease (ILD). Some patients had hematological or solid organ neoplasms. EPID was prevalent, with one case showing rapid progression requiring aggressive treatment.

Discussion and conclusion: This study highlights the association between anti-NOR90 antibodies and systemic autoimmune diseases, particularly SS and ES. EPID was a notable feature, suggesting its consideration in IPAF diagnosis for anti-NOR90 positive patients. Further multicenter studies are needed for better understanding and detection methods optimization.

抗 NOR90 抗体及其临床意义:西班牙南部的多中心经验。
简介:抗NOR90抗体最初是在自身免疫性疾病患者中出现的,其依据是对被称为核极组织者区(NOR)的核极区域的染色。本研究旨在探讨系统性自身免疫疾病患者体内抗 NOR90 抗体的临床方面:方法:对抗 NOR90 抗体阳性患者进行观察性研究,使用 EUROLINE 系统性硬化症谱(IgG)试剂盒(Euroimmun,德国)。收集了有关人口统计学、合并症、自身免疫性疾病、治疗和临床表现的数据:结果:15 名患者的抗 NOR90 抗体呈阳性。大多数患者为女性(86.7%),中位年龄为 54 岁。最常见的临床表现是雷诺现象、干燥和间质性肺病(ILD)。一些患者患有血液或实体器官肿瘤。EPID 很普遍,其中一例病情进展迅速,需要积极治疗:本研究强调了抗NOR90抗体与全身性自身免疫性疾病,尤其是SS和ES之间的关联。EPID是一个显著特征,建议在诊断抗NOR90抗体阳性患者的IPAF时予以考虑。为了更好地理解和优化检测方法,需要进一步开展多中心研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信